Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release…
Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release Capsules
- Published
- 16 Jul 2025
- Units affected
- 12,242 30-count bottles
- Agency
- FDA
- Country
- United States
The hazard
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What to do
Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.
- Check the lot number on the box or bottle.
- Talk to your pharmacist or doctor before stopping any prescribed medicine.
- Return the product to the pharmacy for safe disposal.
Product details
Duloxetine Delayed-Release Capsules, USP, 40mg, 30-count bottles, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. NDC 51991-750-33.
- Brand / company
- Breckenridge Pharmaceutical, Inc.
- Codes / lots
- Lot # 230199, Exp. Date 01/31/2026
- Distribution
- U.S. Nationwide
- Recall status
- Ongoing
Source: U.S. Food and Drug Administration, published 16 Jul 2025. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.